Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin versus placebo for coronary plaque progression by polygenic risk in established cardiovascular disease
ACTRN12620001166965Phase 3Recruiting
- Sponsor
- Monash University
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and coronary arteriosclerosis comparing Atorvastatin 40 mg with Placebo (2 arms). Primary endpoint: Change in non-calcified plaque volume. Started Sep 2021; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
cardiac morbiditycoronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12620001166965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001166965.